Redeye provides a research update following the Q3 report published by Alzinova earlier today.
Redeye leaves a comment following Alzinova’s announcement that the FDA has granted Fast Track Designation (FTD) for its lead candidate ALZ-1...
Cereno Scientific’s Q225 results demonstrated steady progress across its clinical assets, with encouraging developments post-period.
Redeye comments on Alzinova’s announcement of having submitted an IND application and a Fast Track Designation request to the FDA for ALZ-10...
The fast-track designation from the FDA in metastatic pancreatic cancer confirms Cantargia's strategy of developing nadunolimab in patients ...
Redeye comments on BioInvent’s first quarter in 2025.
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H1 report.
Mendus has announced that the FDA has granted Fast Track designation to its lead cancer vaccine, vididencel, as a potential maintenance ther...
Redeye sees the FDA's fast track designation for EVX-01 as a validation of the personalised vaccin approach.
Redeye embraces the FDA Fast Track Designation for the evaluation process of Sedana Medical’s solution for inhaled sedation.
Calliditas is in a good position as it is about to launch Nefecon in Europe together with Stada in early 2022.
